Sterile injectable generic drug products
At Leucadia Pharmaceuticals, we reach communities and conditions that are under-served.

About Leucadia Pharmaceuticals

Leucadia Pharmaceuticals is a leader in the generic injectables market. We invest heavily in new product development while also pursuing partnerships and product acquisitions. Our goals are to provide important new generic injectable products to the acute and specialty markets and to reach communities and conditions that are underserved.
Leucadia Pharmaceuticals was established in 2017 as the commercial arm of Custopharm, Inc and is associated with Water Street Healthcare Partners.


We have assembled an executive team with deep experience in the healthcare industry. We’re ready to take Leucadia Pharmaceuticals to the next level.

William (Bill) has nearly 30 years of experience in the pharmaceutical industry. Prior to joining Custopharm and creating Leucadia Pharmaceuticals, Bill was vice president and general manager of Bedford Laboratories, Inc., where he oversaw a portfolio of more than 100 registered generic injectable products. Prior to Bedford Laboratories he held various scientific leadership positions at Amylin, Novartis, ESI-Lederle, and Barr Laboratories. He began his career as an analytical research chemist at Zeneca Pharmaceuticals. Bill holds a PhD degree in Analytical Chemistry from The Ohio State University and a Bachelor of Science degree in Chemistry from Purdue University.

Kara Eiseman has more than 19 years of experience in the pharmaceutical industry. Before joining Leucadia Pharmaceuticals, Kara was vice president of national accounts for WG Critical Care, a generic injectables company. Kara was also director of marketing for Bioniche Pharmaceuticals, which was acquired by Mylan in 2010. In addition, Kara held marketing positions at APP Pharma (now Fresenius Kabi) and Akorn. Kara received her MBA and MS in marketing from Loyola University Chicago, and her BA in economics from Northwestern University.